Guggenheim analyst Vamil Divan initiated coverage of ANI Pharmaceuticals with a Buy rating and $55 price target.
Published first on TheFly
Guggenheim analyst Vamil Divan initiated coverage of ANI Pharmaceuticals with a Buy rating and $55 price target.
Published first on TheFly